{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-21-009799","form_type":"8-K","ticker":"GTHP","cik":"0000924515","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2021-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.302353+00:00","generated_at":"2026-06-29T05:42:06.303276+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Guided Therapeutics passes regulatory review in China; receives $133K payment from SMI","bullets":["Clinical trial at Fudan University approved; trials at 4 centers start Q3 2021.","SMI paid $133,000 first installment; total $510,635 due during study.","Expected payments up to $3M by end 2022 if NMPA approval granted.","Minimum orders of $72M over 4 years post Chinese FDA approval.","LuViva disposable royalty set at $1.90 per unit, adjusted for inflation."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-21-009799","json":"https://secwatch.observer/filing/0001654954-21-009799.json","markdown":"https://secwatch.observer/filing/0001654954-21-009799.md","text":"https://secwatch.observer/filing/0001654954-21-009799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/924515/000165495421009799/0001654954-21-009799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/924515/000165495421009799/gthp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T05:42:06.303276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}